Equities Analysts Offer Predictions for Zynex Inc.’s FY2018 Earnings (ZYXI)

Zynex Inc. (OTCMKTS:ZYXI) – Seethru Equity upped their FY2018 earnings estimates for Zynex in a research note issued to investors on Wednesday. Seethru Equity analyst A. Tandon now anticipates that the company will earn $0.31 per share for the year, up from their previous forecast of $0.28.

Several other equities analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Zynex from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Thursday, November 23rd. ValuEngine lowered shares of Zynex from a “buy” rating to a “hold” rating in a research report on Thursday, January 25th.

Zynex (ZYXI) opened at $4.09 on Monday. The firm has a market cap of $133.08, a PE ratio of 17.83 and a beta of 0.71. Zynex has a 1 year low of $0.26 and a 1 year high of $5.50.

COPYRIGHT VIOLATION WARNING: “Equities Analysts Offer Predictions for Zynex Inc.’s FY2018 Earnings (ZYXI)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://sportsperspectives.com/2018/03/13/equities-analysts-offer-predictions-for-zynex-inc-s-fy2018-earnings-zyxi.html.

About Zynex

Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Earnings History and Estimates for Zynex (OTCMKTS:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply